66. IgA nephropathy Clinical trials / Disease details

Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02571842 (ClinicalTrials.gov)	January 2012	6/10/2015	Rituximab in Recurrent IgA Nephropathy	A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology	Recurrent IgA Nephropathy	Drug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroids	Chulalongkorn University	NULL	Recruiting	18 Years	70 Years	Both	30	Phase 4	Thailand
2	ChiCTR-TRC-09000338	2009-04-01	2009-02-23	Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy	Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy	IgA nephropathy	Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;	The First Affiliated Hospital of Zhejiang University	NULL	Completed	18	70	Male	Group A:60;Group B:60;		China
3	ChiCTR-TRC-06000004	2006-01-01	2006-09-14	ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial	ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial	primary IgA nephropathy	group 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;	The First Hospital, Peking University	NULL	Completed	16	65	Both	group 1:78;group 2:78;		China
4	NCT00378443 (ClinicalTrials.gov)	January 2006	19/9/2006	ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT		Glomerulonephritis, IGA	Drug: prednisone + Inhibace/Cozaar;Drug: Inhibace/Cozaar	Peking University	NULL	Active, not recruiting	16 Years	65 Years	Both		N/A	NULL
5	NCT00318474 (ClinicalTrials.gov)	January 2002	24/4/2006	Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy	A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy	IgA Nephropathy	Drug: Mycophenolate Mofetil (MMF);Drug: MMF Placebo;Drug: ACEi;Drug: FOS	St. Joseph's Hospital and Medical Center, Phoenix	NULL	Terminated	7 Years	70 Years	All	184	Phase 3	United States